Novartis readies reps for new launches

Share this article:
Novartis is boosting its sales force size ahead of anticipated drug launches, the industry trade group, the National Association of Pharmaceutical Sales Representatives (NAPSR) said.

The drugmaker penned a recruitment ad agreement with NAPSR, as the company looks to fill “nearly a thousand sales positions,” according to a release.

Calls to Novartis to obtain further details of the agreement went unreturned at press time.

Novartis is anticipating the approval of Galvus (type 2 diabetes) and Exforge (for hypertension) before the end of 2007's first quarter, chief marketing officer Kurt Graves said during UBS' Global Life Sciences conference in September.

“What we don't want to tell you is how we have set up our field force,” he said. “Every pharma company needs to come up with innovative go-to market strategies,” to be successful.

Nancy Lurker, SVP, chief marketing officer, said Novartis' efforts will undergo changes in light of these launches.  

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union